Biotech CRO InvitroCue Executive director Dr. Steven Fang explains how their technology has disrupted the current clinical trials landscape and the importance of leveraging innovative technologies in meeting future healthcare needs.

Interviewer: Could you please introduce to our international readers the main activities of InvitroCue as well as the milestones since its foundation in 2012?

InvitroCue was founded in early 2013 and it is a spin out technology company from A*Star. Professor Hanry Yu, partner and co-founder of InvitroCue, is the one who developed such technology and I was the one who provided the initial funding to start running our operations. In January 2016 we listed InvitroCue on the Australian Securities Exchange (ASX) in order to strengthen our financials and continue with our business.

To read the full interview, click here.